SOURCE: Implant Sciences Corporation

Implant Sciences Corporation

November 14, 2012 07:00 ET

Japan's Nuclear Power Plants Continue to Purchase Implant Sciences' Explosives Trace Detectors

Customer Since 2008 With Multiple Follow-On Orders

WILMINGTON, MA--(Marketwire - Nov 14, 2012) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced a follow-on order from a nuclear power plant in Japan, which has ordered an additional Quantum Sniffer™ QS-H150 handheld explosives trace detector. To date, Implant Sciences has sold over $1 million worth of Quantum Sniffers to Japan, a large portion of which have been deployed at nuclear power plants.

Japanese nuclear power plants have been customers of Implant Sciences since 2008 and have repeatedly purchased QS-H150 units.

"This customer has used our explosives trace detectors for the past four years," said Implant Sciences President and CEO, Glenn D. Bolduc. "The Japanese market places a high value on our non-radioactive source. This makes the QS-H150 unique and is a key feature in addition to the accuracy, reliability, low cost of ownership, and ease-of-use that make our Quantum Sniffers a favored choice for security experts around the world."

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector

The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the Company's QS-B220 desktop explosives and drugs trace detector has received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact